Thyroid function in Fabry disease before and after enzyme replacement therapy

Minerva Endocrinologica

Volumn 36, Issue 1, 2011, Pages 1-5

  Faggiano, A ^a   Severino, R ^a   Ramundo, V ^a   Russo, R ^a   Vuolo, L ^a   Del Prete, M ^a   Marciello, F ^a   Lombardi, G ^a   Cianciaruso, B ^a   Colao, A ^a   Pisani, A ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Enzyme replacement therapy; Fabry disease; Hypothyroidism

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY; THYROTROPIN;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ECHOGRAPHY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; HUMAN; LONG TERM CARE; MALE; NODULAR GOITER; THYROID FUNCTION; THYROID FUNCTION TEST; THYROTROPIN BLOOD LEVEL;

ADULT; ALGORITHMS; ALPHA-GALACTOSIDASE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; HUMANS; HYPOTHYROIDISM; MALE; MIDDLE AGED; THYROID FUNCTION TESTS; THYROTROPIN; THYROXINE; TIME FACTORS; TRIIODOTHYRONINE;

EID: 79959969235     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Mehta A, Beck M, Linhart A, Sunder-Plassmann G, Widmer U. History of lysosomal storage diseases: an overview. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 1.
2. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54. (Pubitemid 29058114)
3. Fabry H. Angiokeratoma corporis diffusum - Fabry disease: historical review from the original description to the introduction of enzyme replacement therapy. Acta Paediatr Suppl 2002;91:3-5. (Pubitemid 36174140)
4. Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M et al. FOS Investigators Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. J Med Genet 2009;46:548-52.
5. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001;38:750-60. (Pubitemid 33032930)
6. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001;38:769-75. (Pubitemid 33032933)
7. Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M; European FOS Investigators. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 2006;43:347-52.
8. Nistal M, Paniagua R, Picazo ML. Testicular and epididymal involvement in Fabry's disease. J Pathol 1983;141:113-24.
9. Tojo K, Oota M, Honda H, Shibasaki T, Sakai O. Possible thyroidal involvement in a case of Fabry disease. Intern Med 1994;33:172-6.
10. Faggiano A, Pisani A, Milone F, Gaccione M, Filippella M, Santoro A et al. Endocrine dysfunction in patients with Fabry disease. J Clin Endocrinol Metab 2006;91:4319-25. (Pubitemid 44833405)
11. Hauser AC, Gessl A, Lorenz M, Voigtländer T, Födinger M, Sunder-Plassmann G. High prevalence of subclinical hypothyroidism in patients with Anderson-Fabry disease. J Inherit Metab Dis 2005;28:715-22. (Pubitemid 41349259)
12. Gieselmann V. Cellular pathophysiology of lysosomal storage diseases. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 4.
13. Desnick RJ, Dean KJ, Grabowski G, Bishop DF, Sweeley CC. Enzyme therapy in Fabry disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase A isozymes. Proc Natl Acad Sci U S A 1979;76:5326-30. (Pubitemid 10236134)
14. Bishop DF, Calhoun DH, Bernstein HS, Hantzopoulos P, Quinn M, Desnick RJ. Human alpha-galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme. Proc Natl Acad Sci U S A 1986;83:4859-63. (Pubitemid 16075498)
15. Ioannou YA, Zeidner KM, Gordon RE, Desnick RJ. Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am J Hum Genet 2001;68:14-25.
16. Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L et al. A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001;68:711-22. (Pubitemid 32202764)
17. Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GEet al. International Fabry Disease Study Group. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004;75:65-74.
18. De Schoenmakere G, Chauveau D, Grünfeld JP. Enzyme replacement therapy in Anderson-Fabry's disease: beneficial clinical effect on vital organ function. Nephrol Dial Transplant 2003;18:33-5. (Pubitemid 36109109)